CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
-
Review Meta Analysis
Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis.
Testing to determine HER2 status has come into focus since the approval of trastuzumab (Herceptin) for the treatment of HER2-positive breast cancer. We compared the cost-effectiveness of various strategies used to test HER2 status, an important first step toward evaluating the overall cost-effectiveness of trastuzumab therapy. ⋯ The strategy with the lowest cost-effectiveness ratio involved screening all newly diagnosed cases of breast cancer with immunohistochemistry and confirming scores of 2+ or 3+ with fluorescence in situ hybridization testing.